Plot showing associations of 1-unit increase in log IL-6, log CRP, and fibrinogen with HR of endpoints on a log scale (after adjusting for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, triglycerides, BMI, systolic and diastolic blood pressure, current and exsmoking, diabetes, previous CVD, use of antihypertensive therapy, and country).

<p>Plot showing associations of 1-unit increase in log IL-6, log CRP, and fibrinogen with HR of endpoints on a log scale (after adjusting for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, triglycerides, BMI, systolic and diastolic blood pressure, current and exsmoking, diabetes, previous CVD, use of antihypertensive therapy, and country).</p

Baseline characteristics by incident primary combined nonfatal and fatal endpoint (<i>p</i>-value versus no event group).

<p>Please note that because of the design structure of the trial—recruiting more participants with hypertension/smokers and diabetes (and women) into the low risk primary prevention group—the significance or nonsignificance of univariate comparisons in this table could be potentially misleading. <i>p</i>-Values for continuous variables are from two-sample <i>t</i>-test and for categorical variables from chi-squared test.</p>a<p>Values are geometric means (SD) calculated from the log-transformed distribution and the (<i>p</i>-value).</p><p>SD, standard deviation; TIA, transient ischemic attack.</p

Associations of IL-6, CRP, and fibrinogen with risk (HR for 1-unit increase in log IL-6, log CRP, or fibrinogen) of experiencing one of the four categories of events.

<p>Event groupings as defined in the methods. Fatal CVD deaths preceded by nonfatal CVD are excluded. Model A, adjusted for randomized treatment. Model B, adjusted for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, systolic blood pressure, current smoker, diabetes, previous CVD (CHD, stroke, peripheral arterial disease, stroke, and transient ischaemic attack), use of antihypertensive therapy, and country. Model C, Model B+ adjusted for log triglyceride, BMI, diastolic blood pressure, exsmoker (as well as current smoker).</p

Kaplan-Meier time-to-event plots split by tertiles of IL-6 tertiles for (A) nonfatal CVD (<i>n</i> = 667 events), (B) fatal CVD (<i>n</i> = 189 deaths), (C) fatal other CV (<i>n</i> = 37 deaths), and (D) non-CVD mortality (<i>n</i> = 299 deaths).

<p>Kaplan-Meier time-to-event plots split by tertiles of IL-6 tertiles for (A) nonfatal CVD (<i>n</i> = 667 events), (B) fatal CVD (<i>n</i> = 189 deaths), (C) fatal other CV (<i>n</i> = 37 deaths), and (D) non-CVD mortality (<i>n</i> = 299 deaths).</p

Regional plots of non-overlapping loci that were more significantly associated with fibrinogen in the 1000G GWA study, including variants from both the HapMap (red) and 1000G (green) GWA studies.

<p>Regional plots of non-overlapping loci that were more significantly associated with fibrinogen in the 1000G GWA study, including variants from both the HapMap (red) and 1000G (green) GWA studies.</p

Regional plot of 6p21.3, a non-overlapping locus that was more significantly associated with fibrinogen in the HapMap GWA study, including variants from both the HapMap (red) and 1000G (green) GWA studies.

<p>Regional plot of 6p21.3, a non-overlapping locus that was more significantly associated with fibrinogen in the HapMap GWA study, including variants from both the HapMap (red) and 1000G (green) GWA studies.</p

Summary of the differences between HapMap and 1000G imputation for the seven non-overlapping loci.

<p>Summary of the differences between HapMap and 1000G imputation for the seven non-overlapping loci.</p

Summary of the differences between HapMap and 1000G imputation for the 29 overlapping loci.

<p>Summary of the differences between HapMap and 1000G imputation for the 29 overlapping loci.</p

Overlapping loci that were significant in both the HapMap and 1000G GWA studies.

<p>Overlapping loci that were significant in both the HapMap and 1000G GWA studies.</p

Non-overlapping loci that were significant in either the HapMap or 1000G GWA studies.

<p>Non-overlapping loci that were significant in either the HapMap or 1000G GWA studies.</p